<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656474</url>
  </required_header>
  <id_info>
    <org_study_id>GLYC-101-1a</org_study_id>
    <nct_id>NCT00656474</nct_id>
  </id_info>
  <brief_title>Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotex, Inc.</source>
  <brief_summary>
    <textblock>
      Study is intended to evaluate safety and efficacy parameters in patients treated with
      GLYC-101 gel or placebo after laser ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed pilot-study will document feasibility, safety and efficacy of topically applied
      Glucoprime gel (GLYC-101 gel 1.0 %) in promoting wound healing in healthy volunteer subjects
      undergoing retro-auricular Carbon Dioxide Laser Skin Resurfacing (CO2 LSR). The study will
      observe the effects of the topical agent over the course of 1 month following the treatment.
      as a preparation for study GLYC-101-1b (Double-blind, randomized, placebo-controlled Phase 2
      Pilot Study to investigate the safety and efficacy of 1.0 % topically applied GLYC 101
      compared to placebo, in patients undergoing Carbon Dioxide Laser Skin Resurfacing).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Complete Wound Closure (Epithelialization)</measure>
    <time_frame>Over the course of 1 month following the initial treatment.</time_frame>
    <description>Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Wound Epithelialized</measure>
    <time_frame>Day 15 post laser ablation.</time_frame>
    <description>The percentage of wound epithelialized was assessed at Day 15 post laser ablation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLYC-101 Active Retro-auricular Site (1 per participant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Retro-auricular Site (1 per participant)
This arm undergoes laser ablation with subsequent Placebo gel administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Administration of Placebo gel on Day 1, 3 and 5 post ablation.</description>
    <arm_group_label>2 Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYC-101 gel (1.0 %)</intervention_name>
    <description>Administration on Day 1, 3 and 5 post laser ablation.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects meeting all of the following criteria will be considered for admission to the
        study:

          -  Patients giving informed consent for retro-auricular laser ablation between 25 and 55
             years old.

          -  Retro-auricular area is free of any irritation, scars or dermatologic conditions which
             might interfere with the study.

          -  Willing and able to participate in the study and follow all study directions.

          -  Able to read, understand and sign the consent form.

        Exclusion Criteria:

          -  Pregnant, nursing, or planning a pregnancy during the course of the study, as
             determined by the interview and a urine pregnancy test.

          -  Systemic or cutaneous disease that may interfere with the study results.

          -  Presence of irritation or dermatologic skin conditions in the retro-auricular area.

          -  Known allergies to materials within the test formulations.

          -  Systemic or cutaneous therapy with medication that impacts wound healing (steroids,
             immune modulators, immune suppressants).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Joseph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CLINICAL TESTING CENTER of BEVERLY HILLS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CLINICAL TESTING CENTER of BEVERLY HILLS</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <results_first_submitted>June 23, 2011</results_first_submitted>
  <results_first_submitted_qc>June 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2011</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>John H. Joseph, MD, 9400 Brighton Way, Suite 203, Beverly Hills, CA 90210</name_title>
    <organization>The Clinical Testing Center of Beverly Hills</organization>
  </responsible_party>
  <keyword>burn wounds</keyword>
  <keyword>wound healing</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred in March 2008 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.</recruitment_details>
      <pre_assignment_details>All subjects needed to meet specific inclusion and exclusion criteria as described in the Eligibility section. Eligible subjects were randomly assigned to receive GLYC-101, 1% or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GLYC-101 and Placebo</title>
          <description>Subjects were randomized to receive GLYC-101 Active gel (1%) on one retro-auricular site and Placebo gel on the opposite retro-auricular site.
GLYC-101 gel (1%) Administration on Day 1, 3 and 5 post laser ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GLYC-101 and Placebo</title>
          <description>Subjects were randomized to receive GLYC-101 Active gel (1%) on one retro-auricular site and Placebo gel on the opposite retro-auricular site.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Complete Wound Closure (Epithelialization)</title>
        <description>Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
        <time_frame>Over the course of 1 month following the initial treatment.</time_frame>
        <population>Analysis was Per Protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>GLYC-101 Active Retro-auricular Site (1 Per Participant)</title>
            <description>GLYC-101 gel (1%) Administration on Day 1, 3 and 5 post laser ablation</description>
          </group>
          <group group_id="O2">
            <title>Placebo Retro-auricular Site (1 Per Participant)</title>
            <description>Placebo gel Administration on Day 1, 3 and 5 post laser ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Wound Closure (Epithelialization)</title>
          <description>Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
          <population>Analysis was Per Protocol.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="15" upper_limit="15"/>
                    <measurement group_id="O2" value="15" lower_limit="15" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Wound Epithelialized</title>
        <description>The percentage of wound epithelialized was assessed at Day 15 post laser ablation.</description>
        <time_frame>Day 15 post laser ablation.</time_frame>
        <population>Analysis was Per Protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>GLYC-101 Active Retro-auricular Site (1 Per Participant)</title>
            <description>GLYC-101 gel (1%) Administration on Day 1, 3 and 5 post laser ablation</description>
          </group>
          <group group_id="O2">
            <title>Placebo Retro-auricular Site (1 Per Participant)</title>
            <description>Placebo gel Administration on Day 1, 3 and 5 post laser ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Wound Epithelialized</title>
          <description>The percentage of wound epithelialized was assessed at Day 15 post laser ablation.</description>
          <population>Analysis was Per Protocol.</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected over the course of 1 month.</time_frame>
      <desc>AEs were collected at baseline and each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>GLYC-101 and Placebo</title>
          <description>Subjects were randomized to receive GLYC-101 Active gel (1%) on one retro-auricular site and Placebo gel on the opposite retro-auricular site.
GLYC-101 gel (1%) Administration on Day 1, 3 and 5 post laser ablation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days. The sponsor can require changes to the communication to remove any confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Reinhard Koenig, CEO</name_or_title>
      <organization>Glycotex</organization>
      <phone>301-670-2825</phone>
      <email>Reinhard.Koenig@glycotexinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

